v3.25.2
Note 7 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities (in shares) 0 250
Convertible Series F Preferred Stock [Member]    
Antidilutive Securities (in shares) [1] 103,578 49,125
Series F Preferred Warrants [Member]    
Antidilutive Securities (in shares) [2] 8,249,867 2,784,922
Common Stock Warrants [Member]    
Antidilutive Securities (in shares) 2,066,809 2,554,536
[1] Calculation assumes conversion of the stated value, and accrued dividends, of the Series F Preferred Stock into Common Stock at the Floor Price of $11.17.
[2] Calculation assumes exercise of the Series F Preferred Warrants for cash into Series F Preferred Stock and subsequent conversion of the Series F Preferred Stock into Common Stock at the Floor Price of $11.17.